APA (7th ed.) Citation

Li, X., Song, Y., Lv, M., Wang, Y., Gao, X., Ma, T., . . . Mao, Y. (2025). A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer. Frontiers Media S.A.

Chicago Style (17th ed.) Citation

Li, Xiangjun, et al. A Real-world Study of Palbociclib Plus Endocrine Therapy with or Without a Short Course Chemotherapy in the First-line Treatment of HR-positive HER2-negative Metastatic Breast Cancer. Frontiers Media S.A, 2025.

MLA (9th ed.) Citation

Li, Xiangjun, et al. A Real-world Study of Palbociclib Plus Endocrine Therapy with or Without a Short Course Chemotherapy in the First-line Treatment of HR-positive HER2-negative Metastatic Breast Cancer. Frontiers Media S.A, 2025.